Syfenac

Syfenac: Protecting Infants and Children from Pneumococcal Infections

Syfenac is a vaccine designed to protect infants and children from serious infections caused by Streptococcus pneumoniae, also known as pneumococcus. This bacterium can lead to invasive diseases, pneumonia, and acute otitis media (middle ear infections). The vaccine is particularly effective in preventing conditions like septicaemia (blood infection), meningitis (infection of the membranes around the brain and spine), and pneumonia.

Syfenac is administered as a suspension for injection and is available only by prescription. The vaccination schedule depends on the child’s age and should be followed according to official recommendations. The vaccine is given by injection into the thigh muscle in infants and into the shoulder muscle in young children.

Syfenac works by teaching the immune system to recognize and defend against the pneumococcal bacterium. It contains polysaccharides extracted from the capsule of S. pneumoniae, which are purified and conjugated to a carrier to enhance recognition by the immune system. The vaccine is also adsorbed onto an aluminium compound to stimulate a better immune response.

Clinical studies have shown that Syfenac significantly reduces the occurrence of acute otitis media caused by S. pneumoniae. The vaccine is expected to provide similar protection against this infection, making it a crucial tool in preventing pneumococcal diseases in infants and children.

For more information about using Syfenac safely and effectively, please refer to the package leaflet or consult your healthcare provider. The European Commission granted marketing authorization for Syfenac in 2009, making it available throughout the European Union.